Cargando…

Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase

Stroke is one of the primary causes of morbidity and death worldwide. While intravenous (IV) thrombolysis with alteplase has been widely proven to be beneficial for acute ischemic stroke patients, it still has many limitations. Tenecteplase, a revised version of alteplase, is a potential alternative...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Nan, Lee, Hangil, Wu, Chuanjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419734/
https://www.ncbi.nlm.nih.gov/pubmed/37576574
http://dx.doi.org/10.4103/bc.bc_70_22
_version_ 1785088596956413952
author Yang, Nan
Lee, Hangil
Wu, Chuanjie
author_facet Yang, Nan
Lee, Hangil
Wu, Chuanjie
author_sort Yang, Nan
collection PubMed
description Stroke is one of the primary causes of morbidity and death worldwide. While intravenous (IV) thrombolysis with alteplase has been widely proven to be beneficial for acute ischemic stroke patients, it still has many limitations. Tenecteplase, a revised version of alteplase, is a potential alternative IV thrombolytic agent that has benefits over alteplase. The aim of this mini-review is to summarize the advancements in IV thrombolysis for severe ischemic stroke, specifically the development and transition from alteplase to tenecteplase.
format Online
Article
Text
id pubmed-10419734
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-104197342023-08-12 Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase Yang, Nan Lee, Hangil Wu, Chuanjie Brain Circ Perspective Stroke is one of the primary causes of morbidity and death worldwide. While intravenous (IV) thrombolysis with alteplase has been widely proven to be beneficial for acute ischemic stroke patients, it still has many limitations. Tenecteplase, a revised version of alteplase, is a potential alternative IV thrombolytic agent that has benefits over alteplase. The aim of this mini-review is to summarize the advancements in IV thrombolysis for severe ischemic stroke, specifically the development and transition from alteplase to tenecteplase. Wolters Kluwer - Medknow 2023-06-30 /pmc/articles/PMC10419734/ /pubmed/37576574 http://dx.doi.org/10.4103/bc.bc_70_22 Text en Copyright: © 2023 Brain Circulation https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Perspective
Yang, Nan
Lee, Hangil
Wu, Chuanjie
Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase
title Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase
title_full Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase
title_fullStr Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase
title_full_unstemmed Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase
title_short Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase
title_sort intravenous thrombolysis for acute ischemic stroke: from alteplase to tenecteplase
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419734/
https://www.ncbi.nlm.nih.gov/pubmed/37576574
http://dx.doi.org/10.4103/bc.bc_70_22
work_keys_str_mv AT yangnan intravenousthrombolysisforacuteischemicstrokefromalteplasetotenecteplase
AT leehangil intravenousthrombolysisforacuteischemicstrokefromalteplasetotenecteplase
AT wuchuanjie intravenousthrombolysisforacuteischemicstrokefromalteplasetotenecteplase